Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Characteristic

Value (N = 80)

Median age, years (range)

60.0 (34–84)

Sex, n (%)

 Male

63 (79)

 Female

17 (21)

Race

 White, n (%)

72 (90)

 Black, n (%)

1 (1)

 Asian, n (%)

1 (1)

 Other

3 (4)

 Information missing

3 (4)

Ethnicity

 Hispanic or Latino

5 (6)

 Not Hispanic or Latino

67 (84)

 Not stated

2 (3)

 Unknown

6 (8)

Variant HCL, n (%)

3 (4)

Splenectomy, n (%)

5 (6)

Number of prior systemic therapies, median (range)

3 (2–11)

 > 3 prior lines, n (%)

39 (49)

Baseline hemoglobin, g/dL, median (range)

11.1 (6.5–16.3)

Baseline neutrophil count, × 103/µL, median (range)

0.81 (0.1–6.2)

Baseline platelet count, × 103/µL, median (range)

68.0 (6.0–350.0)

Prior cancer therapy, n (%)

 PNA

80 (100)

 Rituximab

60 (75)

 BRAF inhibitor

14 (18)

 Interferon-α

20 (25)

 Other

8 (10)

Unfit for PNA re-treatment, n (%)

30 (38)

 At risk of infectiona

20 (25)

 Active infectionb

19 (24)

Patients refractory to PNA,c n (%)

39 (49)

 PNA monotherapyd

29 (36)

 PNA + rituximabe

15 (19)

  1. HCL hairy cell leukemia, OR overall response, PNA purine nucleoside analog
  2. aPatients whose baseline absolute neutrophil count was < 0.5 × 103/µL
  3. bPatients whose medical history included a serious infection or febrile neutropenia marked as ‘ongoing’ or ending after the first dose of moxetumomab
  4. cPatients whose HCL was refractory to any line of PNA. Note: A patient was counted as having HCL refractory to PNA monotherapy and/or PNA + rituximab
  5. dPatients who did not achieve an OR or who achieved an OR lasting < 1 year
  6. ePatients who did not achieve an OR or who achieved an OR lasting < 2 years